-
Indian great Ashwin out of Australia's BBL after knee surgery
-
Indian Sikh pilgrims enter Pakistan, first major crossing since May conflict: AFP
-
Asian markets slip as traders eye tech rally, US rate outlook
-
Nintendo hikes Switch 2 annual unit sales target
-
Typhoon flooding kills 5, strands thousands in central Philippines
-
Jobe Bellingham finding his feet as Dortmund head to City
-
US civil trial to hear opening arguments on Boeing MAX crash
-
Jamie Melham on Half Yours only second woman to win Melbourne Cup
-
Myanmar scam hub sweep triggers fraudster recruitment rush
-
Biggest emitter, record renewables: China's climate scorecard
-
Floods strand people on roofs as typhoon pounds Philippines
-
Asian markets swing as trades eye tech rally, US rate outlook
-
South Korea to triple AI spending, boost defence budget
-
Trott to leave as Afghanistan coach after T20 World Cup
-
Late queen's fashion to go on show at Buckingham Palace
-
In Morocco, exiled Afghan women footballers find hope on the pitch
-
EU scrambles to seal climate deal ahead of COP30
-
New Yorkers expected to pick leftist Mamdani in stunning election
-
Pining for Pinochet: how crime fanned nostalgia for Chile's dictator
-
Why an Amazon chef said no to a vegan dinner for Prince William event
-
Cement maker Lafarge on trial in France on charges of funding jihadists
-
Worker dies after medieval tower partly collapses in Rome
-
Run-machine Labuschagne in form of his life ahead of Ashes
-
Prince William plays football, volleyball in Rio on climate trip
-
Jamaicans mobilize aid in aftermath of Melissa's wreckage
-
Starbucks cedes China control to Boyu Capital
-
'Wild at Heart' actress Diane Ladd dies at 89
-
Xhaka lifts Sunderland into fourth after Everton draw
-
Brazil records biggest annual fall in emissions in 15 years: report
-
Victor Conte, mastermind of BALCO doping scandal, dead at 75: company
-
Trial opens in 1st US civil case on 2019 Boeing MAX crash
-
Barrett brothers out of All Blacks' clash with Scotland
-
Medieval tower partially collapses in Rome, trapping worker
-
Arsenal's Arteta says injured Gyokeres out of Slavia Prague tie
-
Alonso says 'quality' Wirtz helped get him Real Madrid job
-
US Fed's Cook warns inflation to stay 'elevated' next year
-
Blue heaven: huge crowds salute Los Angeles Dodgers in victory parade
-
Dutch centrist Jetten clinches election win: final tally
-
Mamdani extends olive branch to anxious NY business community
-
Sierra Leone chimpanzee sanctuary reopens after deforestation protest
-
Shein bans sex dolls after France outrage over 'childlike' ones
-
England full-back Steward doubtful for Autumn rugby clash with Fiji
-
Bayern know how to 'hurt' PSG, says Neuer
-
Rybakina downs Swiatek to reach WTA Finals last four
-
Ex-France international Ben Yedder to stand trial on rape charges
-
Djokovic confirmed for ATP Finals, says Italian federation boss
-
Trent should be remembered for 'great' Liverpool moments, says Slot
-
Stock markets diverge despite boost from AI deals
-
Prince William awed by Rio on climate-focused trip to Brazil
-
Violence in Sudan's El-Fasher could be war crimes, says top court
Baby formula plant linked to US shortage resumes production
Production resumed Saturday at an Abbott Nutrition baby formula plant in the US whose closure helped fuel a crippling nationwide shortage.
The facility in Sturges, Michigan has met initial government sanitary requirements for reopening, the company said in a statement.
The plant shut down in February after the death of two babies, and issued a product recall amid concerns over bacteria contamination.
Shortages of specialized formula were particularly worrying to parents of infants with allergies or with certain metabolic conditions.
Concerns became so acute that President Joe Biden met this week with infant food executives and said his administration was doing everything it could to help.
Abbott said Saturday that it was restarting production of its EleCare formula and that the product should be back on store shelves around June 20.
"We're also working hard to fulfill the steps necessary to restart production of Similac and other formulas," Abbott said.
"We will ramp production as quickly as we can while meeting all requirements."
The United States has been struggling with the shortages for months.
Initially caused by supply chain blockages and a lack of workers due to the pandemic, the shortage was exacerbated when Abbott closed its Sturges plant.
Regulators forced the shutdown amid complaints the plant did not adequately protect against contamination from bacteria.
"Frankly, the inspection results were shocking," FDA chief Robert Califf said last month.
There was standing water in key equipment "that present the potential for bacterial contamination," leaks in the roof and a lack of basic hygiene facilities, he said.
But Abbott officials, while apologizing for the shortage, have said there is no conclusive evidence linking the formula to infant illnesses or deaths.
Abbott's Michigan plant is one of the largest formula factories in the United States.
F.Pavlenko--BTB